News & Events
Published On: 8/17/2020
TARGET-DERM Real-World Evidence Study Reaches 1,000 Enrolled Participants
Target RWE, an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes, has announced its TARGET-DERM registry reached 1,000 enrolled participants.
“I am pleased to share that our TARGET-DERM registry has officially reached 1,000 enrolled patients since its launch in 2019,” said Target RWE CEO Neal Bibeau. “Today’s announcement is a testament to the hard work and effort from our dedicated team members and site investigators.”
Target RWE’s active dermatology registry, TARGET-DERM, generates real-world data for several immune-mediated inflammatory skin conditions (IMISCs), currently focusing on patients being managed for atopic dermatitis. Eventually, it will include patients with hidradenitis suppurativa (painful bumps under the skin), alopecia areata (autoimmune-related hair loss), and vitiligo (loss of skin pigment).
“The academic steering committee is thrilled with the progress that this registry study has made in a short time,” said TARGET-DERM Steering Committee Co-Chair, Emma Guttman-Yassky, MD, PhD, professor and vice chair for research in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai Medical Center. “The quality data in TARGET-DERM will continue to move the field forward by informing natural history of atopic dermatitis and other inflammatory skin conditions and the impact of disease on treatment paradigms.”
The TARGET-DERM longitudinal registry captures three years of retrospective record data and five years of prospective record data, upon consent, of both adult and pediatric patients from geographically dispersed academic and community sites across the United States. Target RWE plans to expand its TARGET-DERM participating sites to Europe and Canada soon. The TARGET-DERM real-world data collection includes the following biospecimen samples: whole blood, saliva, serum, and tape strips.
With the first patient enrolled in January 2019, TARGET-DERM is the sixth registry created and sponsored by Target RWE. Additional active Target RWE registries include nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC), chronic hepatitis B (HBV), asthma, and COVID-19.
About Target RWE
Target RWE is a leading health evidence solutions company that generates innovative real-world evidence (RWE) and provides scientific intelligence tools and solutions for pharmaceutical, biotechnology, and other healthcare partners. Specifically designed to address the complexities of the natural history of disease, the drug development process and treatments in real-world settings, Target RWE builds regulatory-grade clinical data sets and applies state of the science epidemiologic methods to produce RWE about patients with specific conditions, symptoms, and therapies used in usual clinical practice.
Target RWE's regulatory-grade data sets and evidence, modern epidemiological methods, and sound scientific principles rendered as software can be utilized to better health outcomes, inform patient health guidelines, and improve overall quality of care. For more information, visit www.targetrwe.com.
984.234.0268 ext 205
10/11/2021Target RWE Inflammatory Bowel Disease Research Presented at UEG Week 2021
09/13/2021Update from Paris NASH 2021: New Target RWE Nonalcoholic Steatohepatitis (NASH) Data Presented at This Year’s Meeting
07/01/2021Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and Sciences
06/29/2021Liver International Publishes Hepatocellular Carcinoma RWE Review
06/22/2021Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger Patients